EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
You can subscribe to receive the EAHP EU Monitor by email here.
World Health Assembly passes resolutions on antimicrobial drug resistance and access to medicinesThe 67th World Health Assembly in Geneva closed its session on 24th May, after adopting more than 20 resolutions on public health issues of global importance, including antimicrobial drug resistance, access to medicines and health technology assessment.
On antimicrobial drug resistance, delegates expressed their growing concern of antimicrobial resistance and urged governments to strengthen national action and international collaboration. This requires sharing information on the extent of resistance and the use of antibiotics in humans and animals. It also involves improving awareness among health providers and the public of the threat posed by resistance, the need for responsible use of antibiotics, and the importance of good hand hygiene and other measures to prevent infections.
The resolution urges Member States to strengthen drug management systems, to support research to extend the lifespan of existing drugs, and to encourage the development of new diagnostics and treatment options.
As requested in the resolution, the World Health Organisation (WHO) will develop a draft global action plan to combat antimicrobial resistance, including antibiotic resistance for presentation to the World Health Assembly for approval next year.
On access to medicines the World Health Assembly approved the World Health Organisation’s strategy to help countries improve access to essential medicines. Key principles include selecting a limited range of medicines on the basis of the best evidence available, efficient procurement, affordable prices, effective distribution systems, and rational use. The WHO Essential medicines list was recognized as a valuable tool that enables countries to identify a core set of medicines which need to be available to provide quality medical care.
On regulatory system strengthening, the World Health Assembly mandated the World Health Organisation to continue its important role globally in medicines regulation through establishing necessary norms and standards, supporting regulatory capacity-building and strengthening safety monitoring programmes.
On health technology assessment, following the adoption of a resolution, WHO will support capacity-building for health technology assessment in countries. It will provide tools and guidance to prioritize health technologies and intensify networking and information exchange among countries to support priority setting.
More information here: http://www.who.int/mediacentre/news/releases/2014/WHA-20140524/en/
European Medicines Agency and European Ombudsman dispute clinical trial transparency plansThe European Medicines Agency (EMA) has rejected suggestions by the European Ombudsman that the EMA could undermine the public's right of access to clinical trial data if it proceeds with its draft policy relating to public access to the data.
The move comes after European Ombudsman Emily O'Reilly, who is responsible for investigating alleged maladministration in EU institutions and bodies, wrote to the EMA expressing concern at "what appears to be a significant change of policy concerning clinical trial data transparency".
After examining the EMA's draft policy relating to public access to the data, the Ombudsman's office said the EMA is envisaging limiting access to clinical trial data by imposing "strict confidentiality requirements". According to the Ombudsman, this would include allowing data only to be seen on screen using an interface provided by the EMA. The Ombudsman also said that the EMA also envisages imposing "wide restrictions" on the use of such data.
The EMA has denied this is the case, saying it intends to make the information publicly accessible online, and that restrictions are designed to prevent those who access the information using it for commercial gain.
More information here: http://www.out-law.com/en/articles/2014/may/european-medicines-agency-rejects-ombudsmans-concerns-on-clinical-data-trial-public-acccess/
Photographs from European Summit on Hospital Pharmacy now availableJournalists, EAHP Member Associations, and others wishing to publicise the finalization of European Statements of Hospital Pharmacy should be aware that a wide range of photographs from the European Summit on Hospital Pharmacy are now available on the EAHP website , with permission and licence for reuse.
Photographs here: /press-room/multi-media/european-summit-hospital-pharmacy-2014
Press release here: /press-room/patients-and-professionals-agree-future-hospital-pharmacy
The June 2014 edition of the European Journal of Hospital Pharmacy is now available!
EJHP Editor Phil Wiffen discusses the value of peer review in a special editorial. The key role of hospital pharmacists in medicine reconciliation is explored in a large study from England covering 45 hospitals. The impact of such services, especially with elderly patients, is highlighted in a study from Sweden. The recent 19th Congress of the EAHP in Barcelona is also reported, as well as a high level event on the topic of barcoding of medicines in UZ Leuven, Belgium. The edition also features an article on the effect of Denosumab and a letter highlighting a new website compiling the literature on pharmacist impact.
More information here: http://ejhp.bmj.com/content/early/2014/04/28/ejhpharm-2013-000393.full
